METHOD FOR DIFFERENTIAL DIAGNOSIS OF ANAEMIA OF CHRONIC DISEASES AND IRON DEFICIENCY ANAEMIA IN PATIENTS WITH HIV INFECTION Russian patent published in 2024 - IPC G01N33/49 G01N33/68 G01N33/90 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology and infectology, and can be used for differential diagnosis of anaemia of chronic diseases (ACD) and iron deficiency anaemia (IDA) in patients with infection caused by human immune deficiency virus (HIV). Blood is sampled and levels of ferritin, tumour necrosis factor α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP) and erythrocyte count in blood serum are measured. Value of the canonical linear discriminant function CLDF₁ is determined using the formula: CLDF₁=8.3-A×0.3-B×1.4-C×2.5+D×1.2+E×1.7, where CLDF₁ is a canonical linear discriminant function; A is the patient’s blood serum ferritin level (mcg/l); B is the level of tumour necrosis factor α (TNF-α) in patient’s blood serum (pg/ml); C is the level of interleukin-6 (IL-6) in the patient's blood serum (pg/ml); D is the number of erythrocytes in the patient's blood serum (×10¹²/l); E is the level of C-reactive protein (CRP) in patient’s blood serum (mg/l). Canonical correlation coefficients of the centroid R are calculated using canonical analysis. For ACD, the centroid value is -2.86, and for IDA – 2.54. In case the value of CLDF₁ is closer to the centroid -2.86, the patient is diagnosed with ACD. If the CLDF₁ value is closer to centroid of 2.54, the patient is diagnosed with IDA.

EFFECT: method enables the earliest possible (from the first contact with the patient) obtaining a reliable individual assessment of the pathogenetic type of anaemia in the patients with HIV infection; their quick division into groups depending on pathogenetic type of anaemia (ACD or IDA); activating and accelerating the decision-making process on the tactics of treating anaemia and its control; increasing the degree of validity of such a decision; reducing the mental load on the participants (medical personnel, patient and his/her relatives) of the therapeutic process; personification of therapy in severe prognostically unfavourable patients; improvement of its results and improvement of continuity between different stages of treatment of patients due to specified diagnosis of severe pathology due to determination of blood levels of ferritin, TNF-α, IL-6, CRP, erythrocyte count and application of canonical linear discriminant function.

1 cl, 2 ex